Selective COX2 inhibition improves whole body and muscular insulin resistance in fructose-fed rats

European Journal of Clinical Investigation

Volumn 38, Issue 11, 2008, Pages 812-819

  Hsieh, P S ^a   Tsai, H C ^a   Kuo, C H ^b   Chan, J Y H ^a   Shyu, J F ^a   Cheng, W T ^c   Liu, T T ^d  

^a NATIONAL DEFENSE MEDICAL CENTER   (Taiwan)

^b UNIVERSITY OF TAIPEI   (Taiwan)

^c TAIPEI VETERANS GENERAL HOSPITAL   (Taiwan)

^d HUALIEN ARMED FORCES GENERAL HOSPITAL   (Taiwan)

Author keywords

Cyclooxygenase 1 inhibitor; Cyclooxygenase 2 inhibitor; Fructose; Insulin resistance; Rats

Indexed keywords

6 OXOPROSTAGLANDIN F1 ALPHA; 8 ISOPROSTANE; CELECOXIB; CYCLOOXYGENASE 1 INHIBITOR; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITOR; FRUCTOSE; GLUCOSE TRANSPORTER 4; GLYCOGEN SYNTHASE; PIROXICAM; THROMBOXANE B2;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BODY WEIGHT; CONTROLLED STUDY; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG EFFECT; ENZYME ACTIVITY; GLUCONEOGENESIS; GLUCOSE TRANSPORT; GLYCOLYSIS; HYPERINSULINEMIA; INSULIN BLOOD LEVEL; INSULIN RESISTANCE; MALE; METABOLIC PARAMETERS; METABOLIC SYNDROME X; NONHUMAN; PRIORITY JOURNAL; RAT; SOLEUS MUSCLE; SYSTOLIC BLOOD PRESSURE;

ANIMALS; BLOOD GLUCOSE; BLOOD PRESSURE; CYCLOOXYGENASE INHIBITORS; FRUCTOSE; IMMUNOBLOTTING; INSULIN; INSULIN RESISTANCE; MALE; PIROXICAM; PYRAZOLES; RATS; RATS, SPRAGUE-DAWLEY; SULFONAMIDES;

EID: 54349089872     PISSN: 00142972     EISSN: 13652362     Source Type: Journal    
DOI: 10.1111/j.1365-2362.2008.02026.x     Document Type: Article

References (35)

1. Duncan BB, Schmidt MI, Pankow JS, Ballantyne CM, Couper D, Vigo A et al. Low-grade systemic inflammation and the development of type 2 diabetes: The Atherosclerosis Risk in Communities Study. Diabetes 2003 52 : 1799 805.
2. Pradhan AD, Manson JE, Rifai N, Buring JE, Ridker PM. C-reactive protein, interleukin 6, and risk of developing type 2 diabetes mellitus. JAMA 2001 286 : 327 34.
3. Schmidt MI, Duncan BB. Diabesity: an inflammatory metabolic condition. Clin Chem Lab Med 2003 41 : 1120 30.
4. Konheim YL, Wolford JK. Association of a promoter variant in the inducible cyclooxygenase-2 gene (PTGS2) with type 2 diabetes mellitus in Pima Indians. Hum Genet 2003 113 : 377 81.
5. Helmersson J, Vessby B, Larsson A, Basu S. Association of type 2 diabetes with cyclooxygenase-mediated inflammation and oxidative stress in an elderly population. Circulation 2004 109 : 1729 34.
6. El Midaoui A, Wu R, de Champlain J. Prevention of hypertension, hyperglycaemia and vascular oxidative stress by aspirin treatment in chronically glucose-fed rats. J Hypertens 2002 20 : 1407 12.
7. Hundal RS, Petersen KF, Mayerson AB, Randhawa PS, Inzucchi S, Shoelson SE et al. Mechanism by which high-dose aspirin improves glucose metabolism in type 2 diabetes. J Clin Invest 2002 109 : 1321 6.
8. Gonzalez-Ortiz M, Martinez-Abundis E, Balcazar-Munoz BR, Robles-Cervantes JA. Inhibition of cyclooxygenase-1 or -2 on insulin sensitivity in healthy subjects. Horm Metab Res 2001 33 : 250 3.
9. Perucca E. Drug interactions with nimesulide. Drugs 1993 46 (Suppl. 1 79 82.
10. Sone H, Takahashi A, Yamada N. Ibuprofen-related hypoglycemia in a patient receiving sulfonylurea. Ann Intern Med 2001 134 : 344.
11. Rutledge AC, Adeli K. Fructose and the metabolic syndrome: pathophysiology and molecular mechanisms. Nutr Rev 2007 65 : S13 23.
12. Miller A, Adeli K. Dietary fructose and the metabolic syndrome. Curr Opin Gastroenterol 2008 24 : 204 9.
13. Burdan F. Comparison of developmental toxicity of selective and non-selective cyclooxygenase-2 inhibitors in CRL:(WI) WUBR Wistar rats - DFU and piroxicam study. Toxicology 2005 211 : 12 25.
14. Burdan F, Szumilo J, Marzec B, Klepacz R, Dudka J. Skeletal developmental effects of selective and nonselective cyclooxygenase-2 inhibitors administered through organogenesis and fetogenesis in Wistar CRL:(WI) WUBR rats. Toxicology 2005 216 : 204 23.
15. Yoshino T, Kimoto A, Kobayashi S, Noguchi M, Fukunaga M, Hayashi A et al. Pharmacological profile of celecoxib, a specific cyclooxygenase-2 inhibitor. Arzneimittel-Forschung 2005 55 : 394 402.
16. Hsieh PS. Attenuation of insulin-mediated pressor effect and nitric oxide release in rats with fructose-induced insulin resistance. Am Jhypertens 2004 17 : 707 11.
17. Kristiansen S, Nielsen JN, Bourgoin S, Klip A, Franco M, Richter EA. GLUT-4 translocation in skeletal muscle studied with a cell-free assay: involvement of phospholipase D. Am J Physiol Endocrinol Metab 2001 281 : E608 18.
18. Camps M, Castello A, Munoz P, Monfar M, Testar X, Palacin M et al. Effect of diabetes and fasting on GLUT-4 (muscle/fat) glucose-transporter expression in insulin-sensitive tissues. Heterogeneous response in heart, red and white muscle. Biochem J 1992 282 : 765 72.
19. Oakes ND, Cooney GJ, Camilleri S, Chisholm DJ, Kraegen EW. Mechanisms of liver and muscle insulin resistance induced by chronic high-fat feeding. Diabetes 1997 46 : 1768 74.
20. Galipeau D, Arikawa E, Sekirov I, McNeill JH. Chronic thromboxane synthase inhibition prevents fructose-induced hypertension. Hypertension 2001 38 : 872 6.
21. Allsop JR, Wolfe RR, Burke JF. The reliability of rates of glucose appearance in vivo calculated from constant tracer infusions. Biochem J 1978 172 : 407 16.
22. Young AA, Bogardus C, Wolfe-Lopez D, Mott DM. Muscle glycogen synthesis and disposition of infused glucose in humans with reduced rates of insulin-mediated carbohydrate storage. Diabetes 1988 37 : 303 8.
23. Giaccari A, Rossetti L. Predominant role of gluconeogenesis in the hepatic glycogen repletion of diabetic rats. J Clin Invest 1992 89 : 36 45.
24. Rossetti L, Giaccari A. Relative contribution of glycogen synthesis and glycolysis to insulin-mediated glucose uptake. A dose-response euglycemic clamp study in normal and diabetic rats. J Clin Invest 1990 85 : 1785 92.
25. Koopmans SJ, Mandarino L, DeFronzo RA. Time course of insulin action on tissue-specific intracellular glucose metabolism in normal rats. Am J Physiol 1998 274 : E642 50.
26. FitzGerald GA, Patrono C. The coxibs, selective inhibitors of cyclooxygenase-2. N Engl J Med 2001 345 : 433 42.
27. FitzGerald GA, Loll P. COX in a crystal ball: current status and future promise of prostaglandin research. J Clin Invest 2001 107 : 1335 7.
28. McAdam BF, Catella-Lawson F, Mardini IA, Kapoor S, Lawson JA, FitzGerald GA. Systemic biosynthesis of prostacyclin by cyclooxygenase (COX)-2: The human pharmacology of a selective inhibitor of COX-2. Proc Natl Acad Sci USA 1999 96 : 272 7.
29. Whelton A, Schulman G, Wallemark C, Drower EJ, Isakson PC, Verburg KM et al. Effects of celecoxib and naproxen on renal function in the elderly. Arch Intern Med 2000 160 : 1465 70.
30. Lee E, Choi M-K, Youk H-J, Kim C, Han I-O, Yoo B-C et al. 5-(4-Chlorophenyl)-1-(4-methoxyphenyl)-3-trifluoromethylpyrazole acts in a reactive oxygen species-dependent manner to suppress human lung cancer growth. J Cancer Res Clin Oncol 2006 132 : 223 33.
31. Huang Y, Liu J, Wang L-Z, Zhang W-Y, Zhu X-Z. Neuroprotective effects of cyclooxygenase-2 inhibitor celecoxib against toxicity of LPS-stimulated macrophages toward motor neurons. Acta Pharmacol Sin 2005 26 : 952 8.
32. Eriksson JW. Metabolic stress in insulin's target cells leads to ROS accumulation - a hypothetical common pathway causing insulin resistance. FEBS Lett 2007 581 : 3734 42.
33. Alpert E, Gruzman A, Tennenbaum T, Sasson S. Selective cyclooxygenase-2 inhibitors stimulate glucose transport in L6 myotubes in a protein kinase co-dependent manner. Biochem Pharmacol 2007 73 : 368 77.
34. Widlansky ME, Price DT, Gokce N, Eberhardt RT, Duffy SJ, Holbrook M et al. Short- and long-term COX-2 inhibition reverses endothelial dysfunction in patients with hypertension. Hypertension 2003 43 : 310 5.
35. McAdam BF, Catella-Lawson F, Mardini IA, Kapoor S, Lawson JA, FitzGerald GA. Systemic biosynthesis of prostacyclin by cyclooxygenase (COX)-2: the human pharmacology of a selective inhibitor of COX-2. Proc Natl Acad Sci USA 1999 96 : 272 7.